How Trump's tariffs are reshaping Indian pharma
US tariffs may not impact Indian pharma in the short term, but building replacement capacity on US soil remains cost-prohibitive for thin-margin producers. At the same time, a Deloitte survey reveals CXOs want to prioritize specialty expansion.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (0)